Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Stock Information for Revelation Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revelation Biosciences Inc.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.